Didn’t Apply for DEA Registration?Your Supply Chain May Still Be at Stake
Federal registration developments can affect your trading partners and your own legal exposure. Businesses should not assume registration is merely an optional commercial choice.
If a customer needs to replace suppliers to participate in the federal medical cannabis system, your sales are affected. If a manufacturing partner shifts its capacity toward that system, your production arrangements may change. Those consequences reach businesses that never submitted a federal application.
But the issue goes beyond trading relationships. Businesses also need to evaluate whether their own activities require federal registration and what enforcement exposure exists without it. 21 U.S.C. § 822 generally requires registration for manufacturing, distributing, or dispensing controlled substances, subject to applicable exceptions. A decision not to apply does not itself exempt a business from federal law.
For ongoing coverage, subscribe to The Federal Cannabis File. These updates matter to the businesses surrounding DEA applicants, too.
The supply-chain issue is already here
Under DEA’s current guidance, paragraphs 5–8, covered medical cannabis transactions may occur between qualifying timely applicants and appropriately authorized DEA registrants. Businesses that did not apply, applied late, or submitted incomplete applications must obtain registration before participating in those covered transactions. DEA identifies transactions with ineligible counterparties as potential grounds for denial or revocation.
Timely-applicant treatment requires a completed application and applicable fee submitted April 28–June 26, 2026, a still-pending application, and the requisite state medical license. The underlying pending-application provision appears in 21 C.F.R. § 1301.13(k)(7), adopted in the April final rule. An application is not an approval.
The commercial consequence is straightforward: a relationship that worked under the state market’s existing arrangements may need to change when one party pursues the federal medical pathway.
Your customer’s compliance decision can become your revenue problem
Consider a few practical scenarios:
- A cultivator loses a buyer. A medical manufacturer reviewing its eligible suppliers may need to stop purchasing from a cultivation business that never applied and has not obtained registration.
- A brand loses production capacity. Its manufacturing partner may change the products, customers, or arrangements it is willing to support as it reorganizes around federal medical operations.
- A retailer needs replacement products. A supplier that prioritizes the medical channel may reduce its adult-use offerings or change delivery schedules and pricing.
- A distributor’s customer base changes. If key accounts move into a more restricted medical supply chain, the distributor may need to reassess which relationships remain available.
These are potential business consequences, not a claim that every company will face the same disruption. Your commercial exposure depends on the businesses you rely on. Your legal exposure also requires a separate assessment of the authority for your own activities.
November 29 matters beyond the applicants watching the date
In paragraph 11, DEA expects timely applicants to verify partners, adjust supply chains, and establish compliant supply chains by November 29, 2026.
A nonapplicant may therefore feel the consequences before that date: a customer may request status documentation, reconsider a purchase order, or begin qualifying replacement suppliers.
Paragraph 11 separately allows Timely Dispenser Applicants and Timely Distributor Applicants to continue possessing, dispensing, and distributing existing Schedule III medical marijuana inventory acquired before the guidance was issued, including inventory obtained from entities that were neither qualifying timely applicants nor DEA registrants. That inventory may continue to be used in otherwise authorized activities.
The paragraph does not require that qualifying inventory be sold or destroyed by November 29. Its inventory allowance is limited to the identified applicant categories and pre-issuance inventory. For nonapplicants, the business concern is how trading partners adjust ongoing sourcing relationships, rather than an assumed November 29 cutoff for all existing stock. The document states that it is guidance without the force of law.
Adult-use businesses have a reason to follow this, too
The April 28 final rule established a Schedule III pathway for specified medical marijuana products and activities. DOJ’s October 30 announcement, updated November 3, confirms that the order does not authorize recreational marijuana and that marijuana outside its scope remains subject to Schedule I controls.
The business implications can extend across an entire state market. Where medical and adult-use businesses draw on overlapping manufacturers, distributors, brands, facilities, or investment, changes in the medical channel can affect product availability, capacity, pricing, and commercial priorities elsewhere.
Businesses need to plan for the possibility that the federal commercial pathway remains focused on medical cannabis. That is already the focus of the current registration framework. If that divide persists, it could influence which operations companies expand, which customers they serve, and where they invest.
That is a planning scenario, not a prediction that state adult-use markets will disappear. An adult-use business can face a very different competitive environment even without a change to its own state license.
The broader rescheduling proceeding is a separate issue
The broader proposed rescheduling of marijuana remains a separate administrative proceeding. It concerns the broader scheduling question, including nonmedical marijuana outside the current medical rule. DOJ expressly distinguishes that proceeding from the medical registration framework already being implemented.
If non-medical marijuana moves to Schedule III, businesses should take seriously the possibility that registration will be required for the activities they intend to continue. Schedule III remains a controlled-substance category. Broader rescheduling would not, by itself, authorize existing state adult-use operations or eliminate federal registration requirements. The final action would need to be examined for eligibility, permitted activities and any transition provisions.
Businesses should evaluate current obligations and enforcement exposure while following that proceeding. Neither uncertainty about future rules nor difficulty obtaining approval establishes permission to continue operating without required federal authority.
What businesses that did not apply should review now
- What federal authority does the business need? Evaluate whether current or proposed activities require registration, whether any exception or interim authority applies, and the present and future enforcement exposure of operating without required authority.
- Which relationships matter most? Identify the suppliers, manufacturers, distributors, and customers whose departure would materially affect revenue or operations.
- What are those partners planning? Ask whether they are pursuing the medical pathway, changing their business mix, or revisiting existing arrangements.
- What do the agreements say? Review status disclosures, notice requirements, regulatory-change provisions, exclusivity, minimum purchases, supply commitments, and any agreed cure, suspension, or termination process.
- What is the backup plan? Identify alternatives before a key partner changes direction, and evaluate the legal requirements for the particular entities, premises, products, and activities involved.
Following the DEA’s implementation is part of protecting both business relationships and the business’s legal position. The question is not simply whether registration would help sales. Operators need to understand whether it is required for their activities, whether a viable path to approval exists, and what exposure remains if they continue without it.
Frequently asked questions
Why should my business follow DEA updates if we never applied?
Because your own federal obligations and enforcement exposure need evaluation, even if you never applied. Your suppliers, customers, and manufacturing partners may also be changing their operations, affecting revenue, product availability, and production arrangements.
Does not applying mean my business can operate outside federal registration requirements?
No. Not applying does not create an exemption. The business must evaluate the federal authority required for its activities, any applicable exception, and its enforcement exposure. Barriers to obtaining approval do not themselves authorize unregistered operations.
Is a state cannabis license enough to supply a DEA-registered medical cannabis business?
A state license alone does not establish eligibility for those covered federal medical transactions. DEA’s guidance, paragraphs 5–8, distinguishes qualifying timely applicants and authorized registrants from businesses that must first obtain registration.
Must qualifying existing inventory be sold by November 29?
Paragraph 11 does not set a November 29 sell-through or destruction deadline for qualifying pre-issuance inventory held by Timely Dispenser Applicants and Timely Distributor Applicants. It permits continued use of that inventory in otherwise authorized activities, including where it came from nonqualifying suppliers.
Could these developments affect a business that serves only the adult-use market?
Yes. A shared supplier may redirect capacity, a brand may change manufacturing arrangements, or a distributor may prioritize medical accounts. These are potential commercial effects even where the adult-use business did not seek DEA registration.
Will the broader rescheduling proceeding resolve these supply-chain issues?
Businesses should not assume that its outcome will preserve their trading relationships or authorize existing operations. Moving non-medical marijuana to Schedule III would not by itself eliminate registration requirements. The final action and the existing medical framework must both be evaluated.
Stay informed before a trading partner changes course
Subscribe to The Federal Cannabis File for updates on DEA registration, rescheduling, and the practical questions they raise for cannabis businesses.
If you want help evaluating your business’s federal supply-chain exposure, contact Ryan Kocot. State-law questions outside California, Massachusetts, and New York require coordination with appropriately admitted counsel.
Get federal cannabis updatesAttorney advertising. General information only, not legal advice. Reading this article does not create an attorney-client relationship. Ryan Kocot is admitted in California, Massachusetts, and New York. Federal developments discussed are current as of November 16, 2026.

